Castle Biosciences Inc (CSTL) shareholders
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RTW Investments, LP Joint filing with Roderick Wong (9.30%) | 2,758,335 | 9.30% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 2,338,005 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
| Roderick Wong Joint filing with RTW Investments, LP (7.20%) | 2,115,237 | 7.20% | 13G (passive) | Dec 31, 2025 |
| Principal Global Investors, LLC | 1,585,639 | 5.89% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CSTL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,291,963 | 10.78% | $78.51M | +309,017 | 0.00% |
| Rtw Investments, LP | 2,778,335 | 9.09% | $66.26M | +20,000 | 0.57% |
| Principal Financial Group Inc | 1,726,648 | 5.65% | $41.18M | −43,229 | 0.02% |
| Vanguard Capital Management LLC | 1,226,497 | 4.01% | $29.25M | +48,975 | 0.00% |
| Acadian Asset Management LLC | 918,668 | 3.01% | $21.90M | +434,227 | 0.03% |
| Vanguard Portfolio Management LLC | 840,785 | 2.75% | $20.05M | −20,986 | 0.00% |
| Summit Partners Public Asset Management, LLC | 824,872 | 2.70% | $19.67M | −115,813 | 0.35% |
| State Street Corp | 822,079 | 2.69% | $19.63M | +53,000 | 0.00% |
| Allianz Asset Management GmbH | 811,324 | 2.66% | $19.92M | – | 0.02% |
| Geode Capital Management, LLC | 795,912 | 2.61% | $18.99M | +67,812 | 0.00% |
| Mackenzie Financial Corp | 793,507 | 2.60% | $18.93M | +719,396 | 0.02% |
| Dimensional Fund Advisors LP | 791,085 | 2.59% | $18.87M | −248,676 | 0.00% |
| Jefferies Financial Group Inc. | 647,391 | 2.12% | $15.44M | New | 0.10% |
| Qube Research & Technologies Ltd | 589,300 | 1.93% | $14.05M | +29,717 | 0.01% |
| AIGH Capital Management LLC | 545,101 | 1.78% | $13.00M | −45,500 | 0.82% |
| Renaissance Technologies LLC | 371,200 | 1.22% | $8.85M | −161,600 | 0.01% |
| Goldman Sachs Group Inc | 358,397 | 1.17% | $8.55M | +17,226 | 0.00% |
| Point72 Asset Management, L.P. | 357,317 | 1.17% | $8.52M | New | 0.01% |
| Kennedy Capital Management LLC | 348,371 | 1.14% | $8.31M | New | 0.15% |
| Connor, Clark & Lunn Investment Management Ltd. | 331,727 | 1.09% | $7.91M | −45,355 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 176 | 27M | 89.5% | 24 / 79 | 56 / 30 | 5M | 5M |
| Q1 2026 | 186 | 28M | 90.4% | 29 / 72 | 61 / 36 | 6M | 3M |
| Q4 2025 | 195 | 27M | 89.5% | 43 / 65 | 68 / 17 | 5M | 4M |
| Q3 2025 | 173 | 27M | 87.3% | 37 / 62 | 53 / 15 | 3M | 3M |
| Q2 2025 | 152 | 27M | 86.9% | 16 / 69 | 45 / 42 | 4M | 4M |
| Q1 2025 | 180 | 26M | 84.9% | 30 / 74 | 56 / 44 | 6M | 6M |
| Q4 2024 | 197 | 27M | 87.2% | 40 / 66 | 66 / 27 | 5M | 4M |
| Q3 2024 | 185 | 26M | 84.9% | 43 / 75 | 47 / 16 | 7M | 3M |
| Q2 2024 | 159 | 25M | 82.8% | 32 / 54 | 50 / 23 | 3M | 4M |
| Q1 2024 | 151 | 26M | 86.3% | 18 / 54 | 55 / 17 | 4M | 2M |
| Q4 2023 | 153 | 24M | 79.9% | 37 / 56 | 44 / 18 | 4M | 2M |
| Q3 2023 | 135 | 23M | 75.8% | 22 / 52 | 41 / 16 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
223 funds held CSTL in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CSTL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 852,704 | 2.79% | $20.34M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 781,367 | 2.56% | $18.64M | 0.02% | Jun 30, 2026 |
| SmallCap Fund | 725,138 | 2.37% | $20.30M | 0.97% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 342,655 | 1.12% | $8.17M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 327,806 | 1.07% | $9.18M | 0.03% | Jul 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 312,066 | 1.02% | $6.58M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 278,685 | 0.91% | $6.65M | 0.05% | Jun 30, 2026 |
| Wasatch Micro Cap Fund | 276,685 | 0.91% | $6.60M | 0.98% | Jun 30, 2026 |
| Vanguard Explorer Fund | 275,891 | 0.90% | $7.72M | 0.03% | Jul 31, 2026 |
| Buffalo Small Cap Growth Fund | 239,614 | 0.78% | $5.71M | 1.22% | Jun 30, 2026 |
| iShares Biotechnology ETF | 208,267 | 0.68% | $4.97M | 0.05% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 179,326 | 0.59% | $4.28M | 0.14% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 151,700 | 0.50% | $3.20M | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 151,572 | 0.50% | $3.20M | 0.06% | May 29, 2026 |
| Vanguard Russell 2000 Index Fund | 147,766 | 0.48% | $3.11M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Derek J. Maetzold | Pres. & Chief Exec. Officer, Director | 155,942 | 0.51% | Nov 4, 2026 |
| Tobin W. Juvenal | Chief Commercial Officer | 34,967 | 0.11% | Nov 13, 2026 |
| Kristen M. Oelschlager | Chief Operating Officer | 86,005 | 0.28% | Oct 5, 2026 |
| Frank Stokes | Chief Financial Officer | 35,177 | 0.12% | Aug 18, 2026 |
| Ellen Goldberg | Director | 40,921 | 0.13% | Jun 1, 2026 |
| Kim Caple | Director | 36,121 | 0.12% | Jun 1, 2026 |
| G. Bradley Cole | Director | 32,976 | 0.11% | Jun 1, 2026 |
| Rodney Cotton | Director | 32,998 | 0.11% | Jun 1, 2026 |
| Daniel Bradbury | Director | 35,631 | 0.12% | Jun 1, 2026 |
| Miles Harrison | Director | 35,631 | 0.12% | Jun 1, 2026 |
| Tiffany Olson | Director | 39,573 | 0.13% | Jun 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tobin W. Juvenal Chief Commercial Officer | Nov 11, 2026 | Sale | −3,195 | $35.07 | $112.05K | 32,737 |
| Tobin W. Juvenal Chief Commercial Officer | Nov 11, 2026 | Option exercise | +3,195 | $29.50 | $94.25K | 35,932 |
| Tobin W. Juvenal Chief Commercial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −2,828 | $35.04 | $99.10K | 32,737 |
| Tobin W. Juvenal Chief Commercial Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −3,288 | $32.67 | $107.42K | 35,565 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −325 | $36.81 | $11.96K | 1,396 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −382 | $36.81 | $14.06K | 1,642 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −1,025 | $36.81 | $37.73K | 3,904 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −2,393 | $36.01 | $86.16K | 1,721 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −2,816 | $36.01 | $101.39K | 2,024 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −7,555 | $36.01 | $272.02K | 4,929 |
| Tobin W. Juvenal Chief Commercial Officer | Oct 28, 2026 | Sale(10b5-1 plan) | −5,341 | $36.62 | $195.58K | 38,853 |
| Tobin W. Juvenal Chief Commercial Officer | Oct 28, 2026 | Sale(10b5-1 plan) | −1,237 | $35.58 | $44.01K | 44,194 |
| Tobin W. Juvenal Chief Commercial Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −3,288 | $33.08 | $108.77K | 45,431 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 19, 2026 | Sale(10b5-1 plan) | −2,718 | $31.91 | $86.73K | 4,114 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 19, 2026 | Sale(10b5-1 plan) | −3,198 | $31.91 | $102.05K | 4,840 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 19, 2026 | Sale(10b5-1 plan) | −8,580 | $31.91 | $273.79K | 12,484 |
| Tobin W. Juvenal Chief Commercial Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −3,288 | $33.64 | $110.61K | 48,719 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −2,718 | $35.57 | $96.67K | 6,832 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −3,198 | $35.57 | $113.74K | 8,038 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −8,580 | $35.57 | $305.16K | 21,064 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Oct 5, 2026 | Option exercise | +8,165 | $2.39 | $19.51K | 29,644 |
| Kristen M. Oelschlager Chief Operating Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −1,346 | $36.38 | $48.97K | 13,356 |
| Kristen M. Oelschlager Chief Operating Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −2,807 | $35.75 | $100.35K | 14,702 |
| Kristen M. Oelschlager Chief Operating Officer | Oct 1, 2026 | Option exercise | +4,153 | $3.38 | $14.04K | 17,509 |
| Tobin W. Juvenal Chief Commercial Officer | Sep 30, 2026 | Sale(10b5-1 plan) | −1,034 | $34.20 | $35.36K | 52,007 |
| Tobin W. Juvenal Chief Commercial Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −5,543 | $35.50 | $196.77K | 53,041 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −8,580 | $35.33 | $303.13K | 21,479 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 21, 2026 | Option exercise | +8,580 | $2.39 | $20.51K | 30,059 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −3,198 | $35.33 | $112.99K | 11,236 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −2,718 | $35.33 | $96.03K | 9,550 |
| Tobin W. Juvenal Chief Commercial Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −3,294 | $35.14 | $115.75K | 58,584 |
| Tobin W. Juvenal Chief Commercial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −3,306 | $32.32 | $106.85K | 61,878 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −223 | $32.78 | $7.31K | 21,479 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −83 | $32.78 | $2.72K | 14,434 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −71 | $32.78 | $2.33K | 12,268 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −2,656 | $32.00 | $84.99K | 12,339 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −3,124 | $32.00 | $99.97K | 14,517 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −8,361 | $32.00 | $267.55K | 21,702 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Sep 11, 2026 | Option exercise | +8,584 | $2.39 | $20.52K | 30,063 |
| Kristen M. Oelschlager Chief Operating Officer | Sep 1, 2026 | Option exercise | +4,152 | $3.38 | $14.03K | 17,508 |
| Kristen M. Oelschlager Chief Operating Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −3,952 | $33.36 | $131.84K | 13,556 |
| Kristen M. Oelschlager Chief Operating Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −200 | $34.02 | $6.80K | 13,356 |
| Tobin W. Juvenal Chief Commercial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −1,730 | $32.81 | $56.76K | 65,184 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −257 | $33.14 | $8.52K | 11,277 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Option exercise | +12,428 | $2.39 | $29.70K | 33,907 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −11,472 | $33.14 | $380.18K | 22,435 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −21 | $33.88 | $711 | 11,256 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −21 | $33.88 | $711 | 11,256 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −21 | $33.88 | $711 | 11,256 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −177 | $33.88 | $6.00K | 14,995 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −209 | $33.88 | $7.08K | 17,641 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −956 | $33.88 | $32.39K | 21,479 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −257 | $33.14 | $8.52K | 11,277 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −21 | $33.88 | $711 | 11,256 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −257 | $33.14 | $8.52K | 11,277 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −257 | $33.14 | $8.52K | 11,277 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −2,129 | $33.14 | $70.56K | 15,172 |
| Derek J. Maetzold Pres. & Chief Exec. Officer, Director | Aug 28, 2026 | Sale(10b5-1 plan) | −2,505 | $33.14 | $83.02K | 17,850 |
| Tobin W. Juvenal Chief Commercial Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −9,050 | $35.04 | $317.11K | 66,914 |
| Kristen M. Oelschlager Chief Operating Officer | Aug 25, 2026 | Sale | −5,223 | $34.64 | $180.92K | 72,649 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Castle Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,667 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Tobin W. Juvenal Chief Commercial Officer | Nov 9, 2026 | 13,154 | $452.23K | Nov 9, 2026 | Acquired as compensation -- Restricted Stock Units |
| Derek J. Maetzold Officer | Nov 2, 2026 | 21,438 | $749.04K | Nov 2, 2026 | Acquired as a gift |
| Tobin W. Juvenal Chief Commercial Officer | Oct 13, 2026 | 13,154 | $430.93K | Oct 12, 2026 | Acquired as compensation -- Restricted Stock Units |
| Derek J. Maetzold Officer | Oct 5, 2026 | 28,992 | $1.06M | Oct 5, 2026 | Acquired as a gift |
| Kristen M. Oelschlager Officer | Oct 1, 2026 | 4,153 | $147.56K | Oct 1, 2026 | Exercise of Stock Options |
| Tobin W. Juvenal Chief Commercial Officer | Sep 14, 2026 | 13,177 | $440.64K | Sep 14, 2026 | Acquired as compensation -- Restricted Stock Units |
| Derek J. Maetzold Officer | Sep 11, 2026 | 29,014 | $938.02K | Sep 11, 2026 | Acquired as a gift |
| Tobin W. Juvenal Chief Commercial Officer | Aug 25, 2026 | 22,500 | $787.50K | Aug 25, 2026 | Acquired as compensation -- Restricted Stock Units |
| Kristen M. Oelschlager Officer | Aug 24, 2026 | 24,602 | $841.39K | Aug 24, 2026 | Retitled existing joint account into trust name |
| Franklin M. Stokes Officer | Aug 14, 2026 | 24,908 | $741.49K | Aug 14, 2026 | Restricted Stock |
| Derek J. Maetzold Officer | Aug 14, 2026 | 25,792 | $763.96K | Aug 14, 2026 | Acquired as gift |
| Tobin W. Juvenal Chief Commercial Officer | Jul 31, 2026 | 22,500 | $630.00K | Jul 31, 2026 | Acquired as compensation -- Restricted Stock Units |
| Derek J. Maetzold Officer | Jul 31, 2026 | 67,662 | $1.89M | Jul 31, 2026 | Acquired as gift |
| Derek J. Maetzold Officer | Jul 1, 2026 | 23,844 | $589.19K | Jul 1, 2026 | Acquired as gift |
| Kristen M. Oelschlager Officer | Jun 16, 2026 | 29,911 | $617.96K | Jun 16, 2026 | Exercise of Stock Options |
Congress trades
1 trade in Castle Biosciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Josh Gottheimer NJ05 · joint account | Sold (part) | Mar 15, 2022 | $1K–15K | Apr 17, 2022 |
See a number that looks wrong?